Current Issue
- Volume 182
- Number 1
- January 2025
Editor’s Note
Commentaries
Reviews and Overviews
Publication date: 20 December 2024
Pages21–32During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain psychedelics ...
https://doi.org/10.1176/appi.ajp.20230902Publication date: 20 December 2024
Pages33–46Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-...
https://doi.org/10.1176/appi.ajp.20230890Publication date: 20 December 2024
Pages47–53The last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions,...
https://doi.org/10.1176/appi.ajp.20230914Publication date: 20 December 2024
Pages54–78Objective: The authors critically examine the evidence base for psilocybin administered with psychological support/therapy (PST) in the treatment of psychiatric disorders and offer practical recommendations to guide future research endeavors. Methods: PubMed ...
https://doi.org/10.1176/appi.ajp.20230682Publication date: 20 December 2024
Pages79–103MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as “Ecstasy” or “Molly,” has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a ...
https://doi.org/10.1176/appi.ajp.20230681Articles
Publication date: 20 December 2024
Pages104–113Objective: Depression varies along a difficulty-to-treat spectrum. Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD). The objective of this study was to document the ...
https://doi.org/10.1176/appi.ajp.20231063Publication date: 20 December 2024
Pages114–125Objective: Evidence suggests that psilocybin-assisted therapy (PAT) leads to durable shifts in personality structure. However, such changes have yet to be characterized in disorders of addiction. In this secondary analysis from a randomized controlled ...
https://doi.org/10.1176/appi.ajp.20230887Publication date: 20 December 2024
Pages126–132The psychedelic experience can be challenging. There is a need for a structured framework for providing psychological support to individuals with mental health conditions receiving investigational psilocybin treatment. The primary benefit of such a ...
https://doi.org/10.1176/appi.ajp.20230884Past Issues
View Issues Archive
Vol. 182 | No. 1
Vol. 181 | No. 12
Vol. 181 | No. 11
